NEW YORK (GenomeWeb) – Response Genetics today announced an agreement with DxM Diagnostico Molecular to distribute Response's molecular tests, including the ResponseDx: Tissue of Origin test, in Mexico.
The deal is Response's first in Central America, the company said, adding it currently is pursuing similar agreements in Asia, Europe, and the Middle East.
The Los Angeles-based company acquired the ResponseDx: Tissue of Origin test when it purchased the assets of Pathwork Diagnostics last August. The gene expression test provides a definitive diagnosis for poorly differentiated or metastatic cancers without a clear primary origin.
Response said that in addition to distributing that test, DxM will distribute Response's other targeted molecular tests to hospitals and physician practices in Mexico.
Financial and other terms of the deal were not disclosed.
"One of our initiatives is to increase access to our testing services both domestically and internationally," Response Chairman and CEO Thomas Bologna said in a statement. DxM "will facilitate access to the full complement of our portfolio to Mexican oncologists and pathologists."